As Demand Grows, US Nuclear Energy Industry Faces Looming Crunch In Reactor Fuel Supply

Lilly Slides After New Obesity Pill Prescription Data Disappoints Wall Street Shares of Eli Lilly & Co. fell in New York premarket trading after new industry prescription data for the drugmaker's blockbuster obesity shot Zepbound and recently approved oral weight-loss pill Foundayo disappointed Wall Street analysts. Foundayo generated 3,707 prescriptions in its second week, according to new prescription-tracking data from IQVIA cited by RBC Capital Markets analysts. That compares with 18,410 prescriptions for Novo's oral version of Wegovy during its second week after launch, suggesting Lilly's weight-loss drugs are falling behind...

SK Chairman Warns Global Memory Crunch May Last Until 2030 SK Group Chairman Chey Tae-won warned that the global high-bandwidth memory crunch, driven by AI data center buildouts, will last until the end of the decade. Chey told reporters on the sidelines of Nvidia's annual developer conference, 'GTC 2026,' at the San Jose Convention Center in California on Monday that the memory chip shortage could last another four to five years, with supply unlikely to catch up to demand until 2030. He explained, "The supply shortage problem stems from a wafer shortage,...

DOJ Sues Cloudera For Deliberately Excluding American Workers From High-Paying Tech Jobs The Justice Department on Tuesday sued Cloudera Inc., accusing the enterprise data and artificial intelligence company of deliberately engineering a hiring process that excluded American workers from at least seven lucrative technology positions while the firm pursued permanent residency sponsorship for foreign workers on temporary visas. In a 14-page complaint filed with the Office of the Chief Administrative Hearing Officer, the department’s Civil Rights Division alleges that Cloudera, from March 31, 2024, through at least January 28, 2025, instructed...